PATIENTS

OncoSec exists for you, the patient

At OncoSec Medical, we are currently focused on two tumor indications– checkpoint-refractory, late stage metastatic melanoma and metastatic triple negative breast cancer (mTNBC).  Melanoma is a cancer of the skin.  Most melanomas originate on sun-exposed skin, though they can also develop in other parts of the body, including the eyes and sun-shielded locations like mucous membranes or palms, soles, or under fingernails.  The most dangerous aspect of melanoma is its ability to rapidly spread throughout the body.  Stage IV melanoma typically has spread through the lymph nodes to distant sites in the body such as the liver, lungs, bones and brain. Due to this metastatic tumor burden, stage IV melanoma is often very difficult to treat.  Available treatment options frequently combine surgery with immunotherapy or targeted therapy.  Metastatic TNBC is an aggressive type of breast cancer that has a high recurrence rate within the first five years following diagnosis.  While some breast cancers may express estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2), mTNBC tests negative for all three of these well-known markers.  As a result, mTNBC does not respond to existing cancer drugs designed to target these markers, making it more difficult to treat and typically limiting the therapeutic choices of the mTNBC patient. These choices include surgery, radiation, and chemotherapy. Unfortunately, both of these metastatic cancer types are very difficult to treat and currently there are very few FDA approved treatment options for patients.

PATIENT STORIES

FRAN’S STORY –
LIVING WITH METASTATIC MELANOMA

Fran’s personal experience began in 1996 when her mother was diagnosed with acral lentiginous melanoma, which eventually took her life. In 2017, Fran found a small red dot on her foot and immediately knew what it was – melanoma.
Fran underwent surgery and a series of different treatments but the melanoma still spread throughout her body – including her lung, liver, chest cavity, neck and brain.
Fran then learned about OncoSec’s investigational product, TAVO™ (tavokinogene telseplasmid), from her oncologist and received treatment through the Expanded Access Program. Watch Fran’s story to learn how she “got off a one-way street with a dead end.”

JULIE’S STORY –
LIVING WITH TNBC

When Julie was diagnosed with triple negative breast cancer (TNBC) she didn’t understand exactly what that meant. She went home to do more research and quickly learned that TNBC was the most aggressive type of breast cancer with poorer prognosis because it lacks all three types of receptors that targeted medicines need to effectively treat the cancer. Thus, the primary treatment for TNBC remains chemotherapy.
Julie started chemotherapy treatment but it came at a high cost and the side-effects were debilitating. Ultimately chemotherapy didn’t work for Julie and she found herself “wondering where to go from here.” She describes it as the worst day of her life.
Then Julie learned about TAVO from her doctor and enrolled in the ongoing KEYNOTE-890 clinical trial.
Julie tells her story of an “emotional rollercoaster ride” and “finding hope again” after being diagnosed with TNBC.

SHARON’S STORY –
LIVING WITH METASTATIC MELANOMA

Sharon’s personal journey with cancer began three years ago when she was diagnosed with melanoma. She had no family history of melanoma and was shocked when her doctor told her a mark under her fingernail was actually acral melanoma. She immediately had surgery to remove part of her finger but the cancer still spread up her arm.
Sharon then underwent a cycle of treatments, including checkpoint therapy, that came with side-effects and failed to stop her cancer from spreading. Finally, when Sharon’s cancer had spread to over 50 melanomas, her doctor recommended she enroll in the ongoing KEYNOTE-695 clinical trial evaluating TAVO in combination with KEYTRUDA® (pembrolizumab).
Hear Sharon’s story how she found her “saving grace” and “got her life back” after investigational TAVO treatment.

OncoSec’s TAVO™ plus Electroporation Gene Delivery:
Learn From Physicians and Patients How It Works

OncoSec’s product candidates are investigational and have not been approved by the FDA. The results described in the testimonials may not be representative of the patient experience as the product candidates remain investigational.

WE UNDERSTAND YOUR STRUGGLE

At thirty-one, I was diagnosed with breast cancer. Over the next decade, I endured a second cancer diagnosis, but I never let this disease define me. Today, as a two-time breast cancer survivor, I have the courage to continue my fight every day. I am proud to make a difference as a part of the OncoSec team and be a voice for patients.

KIMBERLY IRVINE
Two-Time Breast Cancer Survivor
Patient Insight & Advocacy Officer

Kim-Irvine-Quote

PATIENT RESOURCES

OncoSec encourages patients and care partners to research and explore educational resources.

LEARN MORE

TAVO CLINICAL TRIALS

Our core technology platform continues to advance through clinical trials for various cancers.

LEARN MORE

SCIENTIFIC
PUBLICATIONS

Our initial clinical trial findings on TAVO are significant but we believe they are just the beginning!

LEARN MORE

PATIENT RESOURCES

 

We believe that knowledge holds the key to developing responsive treatments. OncoSec encourages patients and care partners to research and explore educational resources to better understand cancer and the organizations that are committed to offering treatment and support.

GENERAL CANCER SUPPORT ORGANIZATIONS

MELANOMA SUPPORT ORGANIZATIONS

BREAST CANCER SUPPORT ORGANIZATIONS

GENERAL CANCER SUPPORT ORGANIZATIONS

MELANOMA SUPPORT ORGANIZATIONS

BREAST CANCER SUPPORT ORGANIZATIONS

The above links are to third party sites. OncoSec does not control nor monitor the content.